TY - JOUR
T1 - Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity
T2 - a systematic literature review
AU - Ishida, Masato
AU - Kuroiwa, Yuki
AU - Yoshida, Emiko
AU - Sato, Masayo
AU - Krupa, Dominika
AU - Henry, Nathaniel
AU - Ikeda, Kei
AU - Kaneko, Yuko
N1 - Funding Information:
MI, YK, and MS are employees of Eli Lilly Japan K.K. M.S. possesses shares in Eli Lilly and Company. DK and NH are employees of QuintilesIMS. E.Y. is a former employee of Eli Lilly Japan K.K. KI and YK did not receive any compensation for their input into this article. KI has received research grant, consulting fees, speaking fees, and/or honoraria from Tanabe Mitsubishi Pharma, AbbVie, Bristol-Myers K.K., Eisai, UCB, Pfizer Japan, Takeda Pharmaceutical, Eli Lilly, Astellas Pharma, Chugai Pharmaceutical, and Kyowa Hakko Kirin. YK has received consulting fees, speaking fees, and/or honoraria from AbbVie, Astellas Pharma, Chugai Pharmaceutical, Bristol-Myers K.K., Eisai, Tanabe Mitsubishi Pharma, Pfizer Japan, UCB, Eli Lilly, Taisho-Toyama, Janssen, EA Pharma, Ayumi Pharmaseutical, and Takeda Pharmaceutical. The authors alone are responsible for the content and writing of this article. The study was sponsored by Eli Lilly Japan K.K.
Publisher Copyright:
© 2017, © 2017 Japan College of Rheumatology. Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/9/3
Y1 - 2018/9/3
N2 - Objectives: To identify, describe and summarize evidence on residual symptoms and disease burdens in rheumatoid arthritis (RA) patients qualified as being in remission or low disease activity (LDA). Methods: A systematic literature review (SLR) was conducted according to Cochrane collaboration guidelines. The population of interest was adult patients with RA in remission or LDA. The reported outcomes of interest were any symptoms or burdens. Results: Fifty-one publications were identified through an eDatabase search. Together with 17 articles found through other sources, 68 were included for full text review. The most commonly reported residual symptoms were pain (number of studies = 25), fatigue (n = 21) and morning stiffness (n = 5). Reported disease burdens included mental health (n = 15), sleep disturbances (n = 7) and work productivity (n = 5), impairment in quality of life (n = 21), and functional disability (n = 34). Substantial residual symptoms and disease burdens were found to be present in patients in remission or LDA. Conclusion: This is the first SLR to investigate residual symptoms and disease burdens in RA patients in remission or LDA. The results indicate that despite achieving conventional clinical targets, the disease continues to affect patients, suggesting the existence of unmet need under the current treatment paradigm.
AB - Objectives: To identify, describe and summarize evidence on residual symptoms and disease burdens in rheumatoid arthritis (RA) patients qualified as being in remission or low disease activity (LDA). Methods: A systematic literature review (SLR) was conducted according to Cochrane collaboration guidelines. The population of interest was adult patients with RA in remission or LDA. The reported outcomes of interest were any symptoms or burdens. Results: Fifty-one publications were identified through an eDatabase search. Together with 17 articles found through other sources, 68 were included for full text review. The most commonly reported residual symptoms were pain (number of studies = 25), fatigue (n = 21) and morning stiffness (n = 5). Reported disease burdens included mental health (n = 15), sleep disturbances (n = 7) and work productivity (n = 5), impairment in quality of life (n = 21), and functional disability (n = 34). Substantial residual symptoms and disease burdens were found to be present in patients in remission or LDA. Conclusion: This is the first SLR to investigate residual symptoms and disease burdens in RA patients in remission or LDA. The results indicate that despite achieving conventional clinical targets, the disease continues to affect patients, suggesting the existence of unmet need under the current treatment paradigm.
KW - Low disease activity
KW - remission
KW - residual symptom
KW - rheumatoid arthritis
KW - systematic literature review
UR - http://www.scopus.com/inward/record.url?scp=85041120419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041120419&partnerID=8YFLogxK
U2 - 10.1080/14397595.2017.1416940
DO - 10.1080/14397595.2017.1416940
M3 - Article
C2 - 29251034
AN - SCOPUS:85041120419
SN - 1439-7595
VL - 28
SP - 789
EP - 799
JO - Japanese Journal of Rheumatology
JF - Japanese Journal of Rheumatology
IS - 5
ER -